BioMerieux Cash Flow from Operating Activities 2017-2024 | BMXMF

BioMerieux cash flow from operating activities for the twelve months ending December 31, 2024 was $1.866B, a 12.41% decline year-over-year.

  • BioMerieux annual cash flow from operating activities for 2024 was $0.722B, a 49.79% increase from 2023.
  • BioMerieux annual cash flow from operating activities for 2023 was $0.482B, a 3.7% decline from 2022.
  • BioMerieux annual cash flow from operating activities for 2022 was $0.501B, a 47.84% decline from 2021.

BioMerieux Cash Flow from Operating Activities 2017-2024 | BMXMF

  • BioMerieux annual cash flow from operating activities for 2024 was $0.722B, a 49.79% increase from 2023.
  • BioMerieux annual cash flow from operating activities for 2023 was $0.482B, a 3.7% decline from 2022.
  • BioMerieux annual cash flow from operating activities for 2022 was $0.501B, a 47.84% decline from 2021.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$147.7B
CVS Health (CVS)$90.7B
Elevance Health (ELV)$69.8B
Cencora (COR)$56.2B
DiDi Global (DIDIY)$27.9B
Labcorp Holdings (LH)$23.1B
Natera (NTRA)$22.7B
EUROFINS SCIENT (ERFSF)$14.5B
ICON (ICLR)$13.9B
Medpace Holdings (MEDP)$13.2B
CochLear (CHEOY)$12.9B
Solventum (SOLV)$12.6B
Viatris (VTRS)$12.1B
Caris Life Sciences,�Inc (CAI)$10.8B
Revvity (RVTY)$10.6B
Avantor (AVTR)$9.1B
Charles River Laboratories (CRL)$8.1B
Sonic Healthcare (SKHHY)$7.7B
HealthEquity (HQY)$7.7B
Bausch + Lomb (BLCO)$5.1B
Sotera Health (SHC)$4.7B
BrightSpring Health Services (BTSG)$4.2B
Amplifon S.p.A (AMFPF)$3.9B
GeneDx Holdings (WGS)$3.6B
Alignment Healthcare (ALHC)$3.1B
KindlyMD (NAKA)$3B
Concentras Parent (CON)$2.9B
Surgery Partners (SGRY)$2.9B
Organon (OGN)$2.4B
Premier (PINC)$2.1B